Connect with us

BenzingaEditorial

Healthcare – The Silver Lining of 2020

Published

on

Many of the best stocks in 2020 were healthcare companies focused on two disease areas: trying to stop the spread of COVID-19 and improving survival rates from deadly diseases. Their scientific achievements have been nothing less than extraordinary. By looking at healthcare companies with market caps above $200 million from the beginning of the year until December 1st, here are the top ten that delivered highest returns during the unprecedented pandemic that caused nothing less than an economic turmoil.

  1. Novavax

Novavax’s (NASDAQ:NVAX) journey from micro-cap to mid-cap has been nothing short of breath taking. The vaccine specialist has two potential blockbuster drugs in its pipeline: one for influenza and another for COVID-19. Back in March, the company reported positive phase 3 data from its flu shot candidate, Nano-Flu, and it is currently undergoing pivotal trials of its COVID-19 candidate with data expected in the first quarter of 2021.

  1. Vaxart

Vaxart’s (NASDAQ:VXRT) also went from micro-cap to small-cap in 2020 due to its own development of a COVID-19 vaccine candidate. But while Novavax counted on $1.6 billion from Operation Warp Speed, Vaxart did not pull in any federal funding and had to issue stock to fund its phase 1 trial. Despite its slow progress, potential is immense as unlike all the major vaccine candidates, Vaxart’s COVID-19 vaccine is a pill, not a shot. Any piece of good news can further propel this stock to space.

  1. Cardiff Oncology

Cardiff Oncology (NASDAQ:CRDF) had a minuscule $10.6 million market cap at the beginning of the year but to almost $700 million. Its cancer drug that it licensed for $2 million from a private company is its future billion-dollar opportunity but its lead drug candidate, Onvansertib, is reportedly achieving success in fighting colon tumour while simultaneously being tested for prostate cancer and leukemia in phase 2 trials. Pivotal trials have not been reached yet but the early data was enough to lure in investors.

  1. Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX) ran up from a $15 million valuation to $300 million when it provided an early diagnostic test for COVID-19. Co-Diagnostics already has products on the market and is highly profitable. Early sales of its diagnostics have caused revenue to jump to $47 million in the first three quarters of the year, its sales growth soared over 50,000% in the third quarter, and it boasts a 63% profit margin.

  1. Trillium Therapeutics

Trillium Therapeutics (NASDAQ:TRIL) saw its market cap skyrocket from $29 million to $1.2 billion this year. The biotech company specializes in drugs that shut down the CD47 protein in cancer cells, which instructs the immune system to leave the cancer cells alone. When this protein is shut down, the immune system can kill the cancer cells. While Trillium’s drugs are only in phase 1 trials, early data is beyond promising.

  1. Arcturus Therapeutics

mRNA vaccine developers Pfizer (NYSE: PFE), Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX) made headlines this year as their COVID-19 vaccines proved to be safe and effective. Arcturus Therapeutics (NASDAQ:ARCT) is another such specialist but it is lagging behind due to a lack of funds. Arcturus has vaccine candidates for COVID-19 and the flu, along with a variety of other mRNA drugs in clinical trials, including a possible treatment for cystic fibrosis. Still, it did go up 940% as the world is excited about this new technology.

  1. Celldex Therapeutics

Celldex (NASDAQ:CLDX) shares sold for $2 in January and now, they are standing at approximately $19 as the company got its drugs into clinical trails. The biotech has two cancer drugs in phase 1 trials, and another phase 1 drug for an inflammatory disease that causes hives.

  1. Retractable Technologies

Retractable Technologies (NYSEMKT:RVP) makes syringes with automatic retractable needles which became of vital importance during the pandemic because an accidental needle stick can infect medical workers with a patient’s disease. Retractable saw huge revenue gains this year as the government stockpiled syringes for upcoming vaccination.

  1. Moderna

Moderna had a $6 billion market cap already at the beginning of the year when it did not have any existing drug on the market. But COVID-19 allowed the company to show what it’s got and Moerna delivered by producing a vaccine with 94.1% efficacy. Now Moderna’s market cap is $61 billion with rest of its pipeline that has been validated with mRNA evidence.

  1. Seres Therapeutics

Seres Therapeutics (NASDAQ:MCRB) specializes in the genetic material of all the microscopic bacteria that exist in the gastrointestinal tract and seeks the beneficial gut bacteria. It has even joined forces with Nestle (OTC: NSRGY) on a drug in phase 3 trials for a type of colitis that affects half a million Americans every year, and a phase 2 drug for ulcerative colitis.

An even brighter outlook

Novavax, the best stock in 2020 will continue to soar if its phase 3 trials data is positive. Trillium and Seres have exciting drug platforms that are approaching deadly diseases in an entirely new way. 2020 has been a rough year for most, but investors in these 10 stocks sure had a silver lining and their future could be just as bright if they deliver on the promise.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading
Advertisement TRENDING
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BenzingaEditorial

The EV Industry Is Worth More Than The Traditional Automakers

Published

on

Many things that were considered to be impossible actually happened in 2020. One of them is that electric vehicle makers became more valuable than traditional automakers and by about by about $100 billion, according to Barrons. EV makers are now worth about $1.3 trillion whereas traditional car makers combined have a market capitalization of about $1.2 trillion. This figure includes 100 auto makers around the globe with market caps ranging from $10 million all the way to Tesla’s (NASDAQ: TSLA). Based on its fully diluted share count, Tesla is worth about $1 trillion.

This feat is even more impressive if you consider that this is a much smaller industry based on actual number of cars. The last year taught us that the connection between the stock market and the economy is imprecise at best. However, the fact that technology enabled batteries to overpass ICEs is the kind of disruption that investors look for. Even though Tesla is the main contributor to the value of the EV market, the overall image is just as impressive as three of the top five most valuable are EV makers, with Tesla being followed by NIO (NYSE: NIO) and BYD (OTC: BYDDF). As for traditional automakers, Volkswagen (OTC: VWAGY) and Toyota (NYSE: TM) are the most valuable ones with both undergoing serious investments into electrification.

Traditional automakers are going electric

On Friday, BMW said it aims to double its sales of fully-electric vehicles this year. Including plug-in hybrids, it aims for a 50 percent increase in sales of electrified vehicles versus 2020. It did not give sales volumes for its fully electric vehicles but in data released on Tuesday, BMW said it sold close to 193,000 electrified vehicles, including fully electric and plug-in hybris in 2020. As a reminder, Tesla delivered almost half a million all-electric models last year, which is 75% of General Motor’s (NYSE: GM) third-quarter deliveries.

The automotive industry is at an inflection point

BEVs take approximately 1% of the total market for light vehicles, but the figure rises to about 3% if we include hybrid and plug-in hybrids. Why exactly it takes a relatively small market share to disrupt an industry is a bit of a mystery, but one reason is that more investment capital tends to flow in when market share come is within the 3% to 5% range. As more capital drives more innovation and improvement, investors are lured by high growth rates, bringing in even more capital and this is how success is made. Over the past year, EV makers have raised more than $20 billion in fresh capital, which is a fraction of what traditional auto companies spend on plants and equipment. However, on a per car basis, the EV industry is investing at roughly 10 times the rate of the traditional industry. Add to this President Joe Biden’s aim of a carbon-free future by 2035 and the drive toward adoption of EVs which is already seeing impressive results in Europe, the all-electric future is around the corner.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

Europe and EVs- A Blossoming Relationship

Published

on

Tesla (NASDAQ: TSLA) delivered around 96,000 units to the key European EV market in 2020. But in Europe, Tesla’s cars were overtaken in popularity by Volkswagen (OTC: VWAGY) and Renault (OTC: RNLSY). Sales of electric vehicles by European car makers accelerated rapidly in 2020 amid severe fines for car markers whose fleets don’t meet new emissions targets and generous incentives for buyers to trade in their ICE vehicles.

Volkswagen

Volkswagen reported it delivered 212,000 electric cars across the globe in 2020, which is 158% more than in the year prior. 134,000 of those vehicles were battery-electric vehicles, which grew 197% compared with 2019. Volkswagen also said that its ID. 3 model was the top-selling car in Sweden in December by absolute numbers. All-electric Volkswagen models were on top the Netherlands and Germany, taking approximately 23% of each country’s BEVs market.

Mercedes Benz

On January 8th, Mercedes-Benz-owner Daimler (OTC: DDAIF) said that the brand sold more than 160,000 plug-in hybrids and all-electric vehicles in 2020, representing growth of more than 228% from 2019. The share of EVs in Daimler’s sales mix rose drastically from 2% in 2019 to more than 7% in 2020. Also, Mercedes-Benz brand remained the world’s top-selling luxury carmaker for the fourth consecutive year.

Renault

Renault reported that it doubled its electric-vehicle sales in Europe. While group sales fell more than 21% in 2020, its EV sales grew 100% growth from 2019 to 115,888 vehicles. Moreover, total orders at the end of December 2020 were up by 14% compared to December 2019, which was attributed to new hybrid offerings. EVs were the only good news in an otherwise bleak 2020 for the French carmaker, which underperformed both global and European car markets. At the very least, Renault avoided fines as it met its 2020 EU emissions targets. On January 14th, its chief executive officer Luca de Meo will present a strategy update which is expected  to include reviving some older best-selling models as all-electric models.

BMW

BMW (OTC: BMWYY) which also owns Mini, said that its two brands combined sold 192,646 electric vehicles in 2020 marking an increase of nearly 32% from last year. BMW also met its 2020 EU emissions targets.

Takeaway

European governments have created generous incentives to speed up the adoption of EVs, making them much more affordable. Come 2025 when emission targets become more stricter and threat of fines for not respecting them even greater, Tesla will certainly be playing against fully-fit opponents and could even potentially struggle. An EV-only future looks closer than ever in Europe as the race is now on to challenge Tesla’s leadership.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

Lenovo Makes Its Star Market Debut

Published

on

The COVID-19 pandemic had completely changed the way people work and learn. Operating from home actually turned around declining PC sales. Smartphones have been picking more and more market share from PCs and if there was no pandemic, this would probably still be the case. But instead of decreasing demand, there was record growth in PC sales as video collaboration software was needed to fulfill the need caused by closed offices and schools. The demand generated months and months of production. According to Reuters, sales of desktops, laptops, and tablets are expected to reach the level of 300 million shipments, the first time after its peak in 2008. This made all the PC manufacturers like Dell Technologies Inc. (NYSE: DELL), HP Inc. (NYSE: HPQ), and Lenovo Group Ltd. (OTC: LNVGY) very happy.

Lenovo CDR story

China’s Lenovo Group is listed at the Hong Kong stock exchange, with about 12.04 billion shares outstanding in total as of January 12th. The company decided to issue Chinese Depository receipts (CDRs) which will be up to 10% of the total number of shares to be listed on the Star Market of the Shanghai Stock Exchange. The proceeds from the issuing of CDRs is planned to help the company’s research and development of new technologies, development of new products and solutions, and overall strategic investments in core segments. On Wednesday, the news caused to stock to drove the stock to its highest level since 2015.

The Star Market

The Star Market was launched in 2019 aiming for innovative technology companies that need more relaxed listing rules. In December, the Star Market counted 200 companies. A CDR or Chinese Depositary Receipt is a way for non-Chinese companies to list their shares in China. This is the equivalent to American depositary receipts (ADRs) which allow non-U.S. companies’ shares to trade on American exchange markets. Technically, CDRs and ADRs are not companies’ shares, but they represent an equity interest in a company. Besides Lenovo, an AI startup that specializes in facial recognition called Megvii Technology Ltd will also be among the first companies to benefit from this new structure.

Conclusion

Lenovo’s listing should be a breakthrough for Shanghai’s Science Technology and Innovation Board. Lenovo, a flagship of the Star Market, should attract much more followers and clear a path for many Chinese start-ups to raise capital in their home country. The company’s strong and growing global presence should continue to demonstrate the boom of China’s capital market and attract more investors to invest.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading
Advertisement

TRENDING

Advertisement

Submit an Article

Send us your details and the subject of your article and an IAM editor will be in touch with you shortly

Trending